|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Awad, MM, Liu, S, Rybkin, II, Arbour, KC, Dilly, J, Zhu, VW, Johnson, ML, Heist, RS, Patil, T, Riely, GJ, Jacobson, JO, Yang, X, Persky, NS, Root, DE, Lowder, KE, Feng, H, Zhang, SS, Haigis, KM, Hung, YP, Sholl, LM, Wolpin, BM, Wiese, J, Christiansen, J, Lee, J, Schrock, AB, Lim, LP, Garg, K, Li, M, Engstrom, LD, Waters, L, J Lawson, D, Olson, P, Lito, P, Ou, S-HI, Christensen, JG, Jänne, PA, Aguirre, AJ|
|Journal||N Engl J Med|
|Date Published||2021 06 24|
|Keywords||Acetonitriles, Appendiceal Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Drug Resistance, Neoplasm, Humans, Lung Neoplasms, Mutation, Piperazines, Protein Conformation, Proto-Oncogene Proteins p21(ras), Pyridines, Pyrimidines|
BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS). The mechanisms of acquired resistance to these therapies are currently unknown.
METHODS: Among patients with -mutant cancers treated with adagrasib monotherapy, we performed genomic and histologic analyses that compared pretreatment samples with those obtained after the development of resistance. Cell-based experiments were conducted to study mutations that confer resistance to KRAS inhibitors.
RESULTS: A total of 38 patients were included in this study: 27 with non-small-cell lung cancer, 10 with colorectal cancer, and 1 with appendiceal cancer. Putative mechanisms of resistance to adagrasib were detected in 17 patients (45% of the cohort), of whom 7 (18% of the cohort) had multiple coincident mechanisms. Acquired alterations included G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R, Y96C, and high-level amplification of the allele. Acquired bypass mechanisms of resistance included amplification; activating mutations in , , , and ; oncogenic fusions involving , , , , and ; and loss-of-function mutations in and . In two of nine patients with lung adenocarcinoma for whom paired tissue-biopsy samples were available, histologic transformation to squamous-cell carcinoma was observed without identification of any other resistance mechanisms. Using an in vitro deep mutational scanning screen, we systematically defined the landscape of mutations that confer resistance to KRAS inhibitors.
CONCLUSIONS: Diverse genomic and histologic mechanisms impart resistance to covalent KRAS inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer. (Funded by Mirati Therapeutics and others; ClinicalTrials.gov number, NCT03785249.).
|Alternate Journal||N Engl J Med|
|Grant List||1R01CA230267-01A1 / CA / NCI NIH HHS / United States |
R01 CA230267 / CA / NCI NIH HHS / United States
19-029 MIA / / Mark Foundation For Cancer Research /
K08 CA218420-02 / CA / NCI NIH HHS / United States
1R01CA230745-01 / CA / NCI NIH HHS / United States
R01 CA230745 / CA / NCI NIH HHS / United States
P50 CA127003 / CA / NCI NIH HHS / United States
U01 CA210171 / CA / NCI NIH HHS / United States
CRP-17-111-01-CDD / / American Cancer Society /